Succeeder Technology disclosed its 2026 half-year report. In the first half, it achieved operating revenue of 133 million yuan, down 4.31% year on year. Net profit attributable to shareholders of the listed company was 42.52 million yuan, down 11.41% year on year. Basic earnings per share were 0.41 yuan. The company said the decline was mainly affected by a combination of factors, including medical institutions strengthening management of test item packages, DRG and DIP payment reform, and mutual recognition of test results.
Beijing Succeeder Technology IncRevenue and net profit declined due to medical institutions strengthening management of test item packages, DRG/DIP payment reform, and mutual recognition of test results, reducing demand for its products.
